Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Editorial: AI and Financial Technology.
Giudici P, Hochreiter R, Osterrieder J, Papenbrock J, Schwendner P. Giudici P, et al. Among authors: hochreiter r. Front Artif Intell. 2019 Nov 15;2:25. doi: 10.3389/frai.2019.00025. eCollection 2019. Front Artif Intell. 2019. PMID: 33733114 Free PMC article. No abstract available.
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents.
Buerger V, Hadl S, Schneider M, Schaden M, Hochreiter R, Bitzer A, Kosulin K, Mader R, Zoihsl O, Pfeiffer A, Loch AP, Morandi E Jr, Nogueira ML, de Brito CAA, Croda J, Teixeira MM, Coelho IC, Gurgel R, da Fonseca AJ, de Lacerda MVG, Moreira ED Jr, Veiga APR, Dubischar K, Wressnigg N, Eder-Lingelbach S, Jaramillo JC. Buerger V, et al. Among authors: hochreiter r. Lancet Infect Dis. 2025 Jan;25(1):114-125. doi: 10.1016/S1473-3099(24)00458-4. Epub 2024 Sep 5. Lancet Infect Dis. 2025. PMID: 39243794 Clinical Trial.
The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection.
Weber WC, Streblow ZJ, Kreklywich CN, Denton M, Sulgey G, Streblow MM, Marcano D, Flores PN, Rodriguez-Santiago RM, Alvarado LI, Rivera-Amill V, Messer WB, Hochreiter R, Kosulin K, Dubischar K, Buerger V, Streblow DN. Weber WC, et al. Among authors: hochreiter r. Vaccines (Basel). 2024 Aug 7;12(8):893. doi: 10.3390/vaccines12080893. Vaccines (Basel). 2024. PMID: 39204019 Free PMC article.
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study.
McMahon R, Toepfer S, Sattler N, Schneider M, Narciso-Abraham M, Hadl S, Hochreiter R, Kosulin K, Mader R, Zoihsl O, Wressnigg N, Dubischar K, Buerger V, Eder-Lingelbach S, Jaramillo JC. McMahon R, et al. Among authors: hochreiter r. Lancet Infect Dis. 2024 Dec;24(12):1383-1392. doi: 10.1016/S1473-3099(24)00357-8. Epub 2024 Aug 12. Lancet Infect Dis. 2024. PMID: 39146946 Clinical Trial.
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial.
Ghadge SK, Schneider M, Dubischar K, Wagner L, Kadlecek V, Obersriebnig M, Hochreiter R, Klingler A, Larcher-Senn J, Derhaschnig U, Bender W, Eder-Lingelbach S, Bézay N. Ghadge SK, et al. Among authors: hochreiter r. Lancet Infect Dis. 2024 Nov;24(11):1275-1286. doi: 10.1016/S1473-3099(24)00372-4. Epub 2024 Jul 16. Lancet Infect Dis. 2024. PMID: 39029481 Clinical Trial.
36 results